The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies
Open accessAbstract
Chimeric antigen receptor T (CART) cell immunotherapy has been remarkably successful in treating certain relapsed/refractory hematological cancers. However, CART cell therapy is also associated with toxicities which present an obstacle to its wider adoption as a mainstay for cancer treatment. The primary toxicities following CART cell administration are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). New insights into the mechanisms of these toxicities have spurred novel treatment options. In this review, we summarize the available literature on the clinical manifestations, mechanisms, and treatments of CART-associated CRS and ICANS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
O’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Gross, G., Waks, T., & Eshhar, Z. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10024 · Cited by 1,590
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406
Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0698 · Cited by 1,400
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,230
Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-793141 · Cited by 1,156 · cited 1×
“These researchers also identified several independent predictors of CRS: high tumor burden, prior lymphodepletion with fludarabine and cyclophosphamide, high CART dose, and high peak CART blood counts all correlated with CRS development (32).”
BackgroundGardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,121
Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102
Mechanisms of resistance to CAR T cell therapy
Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 959
Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1319 · Cited by 942
Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843
Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Brudno, J. N., Maric, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler-Stevenson, M., Salem, D., Yuan, C., Pavletic, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 781
Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J., Wright, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0428 · Cited by 764
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Maude, S. L., Barrett, D., Teachey, D. T., & Grupp, S. A. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000035 · Cited by 752
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015) · Blood · doi:10.1182/blood-2014-12-580068 · Cited by 727
Sterner, R. M., Sakemura, R., Cox, M. J., Yang, N., Khadka, R. H., Forsman, C. L., Hansen, M. J., Jin, F., Ayasoufi, K., Hefazi, M., et al. (2019) · Blood · doi:10.1182/blood-2018-10-881722 · Cited by 621
Self-citationPark, J. R., DiGiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H. B., Bautista, C., Chang, W.-C., Ostberg, J. R., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300104 · Cited by 603
Wang, X., Chang, W.-C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600
Hoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Mestermann, K., Giavridis, T., Weber, J., Rydzek, J., Frenz, S., Nerreter, T., Mades, A., Sadelain, M., Einsele, H., & Hudecek, M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5907 · Cited by 531
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679134 · Cited by 474
Klebanoff, C. A., Khong, H. T., Antony, P. A., Palmer, D. C., & Restifo, N. P. (2005) · Trends in Immunology · doi:10.1016/j.it.2004.12.003 · Cited by 469
Fitzgerald, J. C., Weiss, S. L., Maude, S. L., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., Shaw, P., Berg, R. A., June, C. H., Porter, D. L., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002053 · Cited by 459
Mitsuyasu, R. T., Anton, P. A., Deeks, S. G., Scadden, D. T., Connick, E., Downs, M. T., Bakker, A., Roberts, M. R., June, C. H., Jalali, S., et al. (2000) · Blood · doi:10.1182/blood.v96.3.785 · Cited by 425
Thistlethwaite, F. C., Gilham, D. E., Guest, R. D., Rothwell, D. G., Pillai, M., Burt, D. J., Byatte, A. J., Kirillova, N., Valle, J. W., Sharma, S. K., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2034-7 · Cited by 406
Goff, S. L., Morgan, R. A., Yang, J. C., Sherry, R. M., Robbins, P. F., Restifo, N. P., Feldman, S. A., Lu, Y.-C., Lu, L., Zheng, Z., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000260 · Cited by 377
Xu, X., Sun, Q., Liang, X., Chen, Z., Zhang, X., Zhou, X., Li, M., Tu, H., Liu, Y., Tu, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02664 · Cited by 347
Richardson, P. G., Riches, M. L., Kernan, N. A., Brochstein, J. A., Mineishi, S., Termuhlen, A. M., Arai, S., Grupp, S. A., Guinan, E. C., Martin, P. L., et al. (2016) · Blood · doi:10.1182/blood-2015-10-676924 · Cited by 336
Managing the toxicities of CAR T‐cell therapy
Neelapu, S. S. (2019) · Hematological Oncology · doi:10.1002/hon.2595 · Cited by 328
Gauthier, J., Hirayama, A. V., Purushe, J., Hay, K. A., Lymp, J., Li, D. H., Yeung, C. C. S., Sheih, A., Pender, B. S., Hawkins, R. M., et al. (2020) · Blood · doi:10.1182/blood.2019002936 · Cited by 328
Feng, K., Liu, Y., Guo, Y., Qiu, J., Wu, Z., Dai, H., Yang, Q., Wang, Y., & Han, W. (2018) · Protein & Cell · doi:10.1007/s13238-017-0440-4 · Cited by 326
Hege, K. M., Bergsland, E. K., Fisher, G. A., Nemunaitis, J. J., Warren, R. S., McArthur, J. G., Lin, A. A., Schlom, J., June, C. H., & Sherwin, S. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0222-9 · Cited by 325
Deeks, S. G., Wagner, B., Anton, P. A., Mitsuyasu, R. T., Scadden, D. T., Huang, C., Macken, C., Richman, D. D., Christopherson, C., June, C. H., et al. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0611 · Cited by 324
Weinkove, R., George, P., Dasyam, N., & McLellan, A. D. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1049 · Cited by 324
T cell homeostatic proliferation elicits effective antitumor autoimmunity
Dummer, W., Niethammer, A. G., Baccalà, R., Lawson, B. R., Wagner, N., Reisfeld, R. A., & Theofilopoulos, A. N. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15175 · Cited by 308
Feng, K., Guo, Y., Dai, H., Wang, Y., Li, X., Jia, H., & Han, W. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5023-8 · Cited by 290
Gardner, R. A., Ceppi, F., Rivers, J., Annesley, C., Summers, C., Taraseviciute, A., Gust, J., Leger, K. J., Tarlock, K., Cooper, T. M., et al. (2019) · Blood · doi:10.1182/blood.2019001463 · Cited by 286
Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
Taraseviciute, A., Tkachev, V., Ponce, R., Turtle, C. J., Snyder, J. M., Liggitt, H. D., Myerson, D., Gonzalez-Cuyar, L., Baldessari, A., English, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1368 · Cited by 256
Diaconu, I., Ballard, B., Zhang, M., Chen, Y., West, J., Dotti, G., & Savoldo, B. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.01.011 · Cited by 250
Pharmacologic control of CAR-T cell function using dasatinib
Weber, E. W., Lynn, R. C., Sotillo, E., Lattin, J., Xu, P., & Mackall, C. L. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028720 · Cited by 239
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Mahadeo, K. M., Khazal, S. J., Abdel-Azim, H., Fitzgerald, J. C., Taraseviciute, A., Bollard, C. M., Tewari, P., Duncan, C., Traube, C., McCall, D., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0075-2 · Cited by 238
WALKER, R. E., Bechtel, C. M., Natarajan, V., Baseler, M., Hege, K. M., Metcalf, J. A., Stevens, R. A., Hazen, A., Blaese, R. M., Chen, C. C., et al. (2000) · PubMed · doi:10.1182/blood.v96.2.467 · Cited by 222
Yoon, D., Osborn, M., Tolar, J., & Kim, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020340 · Cited by 215
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
Elli, E. M., Baratè, C., Mendicino, F., Palandri, F., & Palumbo, G. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01186 · Cited by 207
Rajasekaran, S., Kruse, K., Kovey, K., Davis, A. T., Hassan, N. E., Ndika, A. N., Zuiderveen, S., & Birmingham, J. (2014) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000000078 · Cited by 198
Ruella, M., Kenderian, S. S., Shestova, O., Fraietta, J. A., Qayyum, S., Zhang, Q., Maus, M. V., Liu, X., Nunez-Cruz, S., Klichinsky, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1527 · Cited by 188
Self-citationBudde, L. E., Berger, C., Lin, Y., Wang, J., Lin, X., Frayo, S. E., Brouns, S. A., Spencer, D. M., Till, B. G., Jensen, M. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082742 · Cited by 186
Locke, F. L., Neelapu, S. S., Bartlett, N. L., Lekakis, L. J., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Timmerman, J. M., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.1547.1547 · Cited by 184
CAR T Cell Toxicity: Current Management and Future Directions
Yáñez, L., Sánchez‐Escamilla, M., & Perales, M. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000186 · Cited by 175
Tasian, S. K., Kenderian, S. S., Shen, F., Ruella, M., Shestova, O., Kozlowski, M., Li, Y., Schrank-Hacker, A., Morrissette, J. J. D., Carroll, M., et al. (2017) · Blood · doi:10.1182/blood-2016-08-736041 · Cited by 167
Self-citationSachdeva, M., Duchateau, P., Depil, S., Poirot, L., & Valton, J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ac119.007558 · Cited by 159
Ceschi, A., Noseda, R., Palin, K., & Verhamme, K. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00557 · Cited by 159
Li, A. M., Hucks, G., DiNofia, A. M., Seif, A. E., Teachey, D. T., Baniewicz, D., Callahan, C. A., Fasano, C., McBride, B., Gonzalez, V. E., et al. (2018) · Blood · doi:10.1182/blood-2018-99-112572 · Cited by 156
Toxicities of CD19 CAR‐T cell immunotherapy
Hirayama, A. V. V., & Turtle, C. J. (2019) · American Journal of Hematology · doi:10.1002/ajh.25445 · Cited by 152
Monocyte lineage–derived IL-6 does not affect chimeric antigen receptor T-cell function
Singh, N., Hofmann, T. J., Gershenson, Z., Levine, B. L., Grupp, S. A., Teachey, D. T., & Barrett, D. M. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.04.001 · Cited by 151 · cited 1×
“These data suggest that direct interactions between CART and host myeloid cells – primarily macrophages – lead to increased IL-6 and iNOS production and subsequent CRS; however, earlier in vitro studies have concluded that direct contact between CART and myeloid cells is not required to produce IL-6 (56).”
BackgroundWohlfarth, P., Agis, H., Gualdoni, G. A., Weber, J., Staudinger, T., Schellongowski, P., & Robak, O. (2017) · Journal of Intensive Care Medicine · doi:10.1177/0885066617711386 · Cited by 142
Gill, S. I., Vides, V., Frey, N. V., Hexner, E. O., Metzger, S. T., O'Brien, M., Hwang, W., Brogdon, J. L., Suhoski, M. M., Fraietta, J. A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007317 · Cited by 138
Ruella, M., Kenderian, S. S., Shestova, O. E., Klichinsky, M., Melenhorst, J. J., Wasik, M. A., Lacey, S. F., June, C. H., & Gill, S. I. (2016) · Leukemia · doi:10.1038/leu.2016.262 · Cited by 133
Self-citationNeuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema
Torre, M., Solomon, I. H., Sutherland, C. L., Nikiforow, S., DeAngelo, D. J., Stone, R. M., Vaitkevicius, H., Galinsky, I. A., Padera, R. F., Trede, N. S., et al. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly064 · Cited by 132
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M. L., Arnason, J. E., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C. B., et al. (2019) · Blood · doi:10.1182/blood-2019-127508 · Cited by 116
Chong, E. A., Svoboda, J., Nasta, S. D., Landsburg, D. J., Winchell, N., Napier, E. B., Mato, A. R., Melenhorst, J. J., Ruella, M., Lacey, S. F., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119502 · Cited by 84
Mahmoudjafari, Z., Hawks, K. G., Hsieh, A. A., Plesca, D. C., Gatwood, K. S., & Culos, K. A. A. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.09.024 · Cited by 80
Kumar, B., Aleem, S., Saleh, H., Petts, J., & Ballas, Z. K. (2017) · Journal of Clinical Immunology · doi:10.1007/s10875-017-0439-x · Cited by 73
Maude, S. L., Barrett, D. M., Ambrose, D. E., Rheingold, S. R., Aplenc, R., Teachey, D. T., Callahan, C. A., Barker, C. S., Mudambi, M., Shaw, P. A., et al. (2015) · Blood · doi:10.1182/blood.v126.23.683.683 · Cited by 29
Park, J. H., Frigault, M. J., Maziarz, R. T., Naim, A. B., Burke, L. M., Tian, C., & Porter, D. L. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.12.436 · Cited by 11
Research works printed but not linked: 9
- Jacoby, 2015, Lineage switch as a relapse mechanism of Pre-B acute lymphoblastic leukemia following CD19 CAR., Blood., 126, 2524, 10.1182/blood.V126.23.2524.2524 · doi:10.1182/blood.v126.23.2524.2524
- Burns, 2019, Comparative review of 30 day non-relapse mortality (NRM) in B-cell lymphomas associated with Anti-CD19 chimeric antigen receptor T-cells (CAR-T) from FDA database, clinical studies, and MD Anderson., Blood., 134, 10.1182/blood-2019-131077 · doi:10.1182/blood-2019-131077
- Dong, 2015, Chimeric antigen receptor 4SCAR19-modified T cells in acute lymphoid leukemia: a phase II multi-center clinical trial in China., Blood., 126, 3774, 10.1182/blood.V126.23.3774.3774 · doi:10.1182/blood.v126.23.3774.3774
- Zhang, 2018, Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient., Blood Adv., 2, 1691, 10.1182/bloodadvances.2018017004 · doi:10.1182/bloodadvances.2018017004
- Kenderian, 2016, Ruxolitinib prevents cytokine release syndrome after CART cell therapy without impairing the anti-tumor effect in a Xenograft model., Blood., 128, 10.1182/blood.V128.22.652.652 · doi:10.1182/blood.v128.22.652.652
- Huarte, 2019, Prophylactic itacitinib (INCB039110) for the prevention of cytokine release syndrome induced by chimeric antigen receptor T-cells (CAR-T-cells) therapy., Blood., 134, 10.1182/blood-2019-128288 · doi:10.1182/blood-2019-128288
- Park, 2017, Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL., J Clin Oncol., 10.1200/JCO.2017.35.15_suppl.7024 · DOI
- Gilbert, Severe neurotoxicity in the phase 2 trial of JCAR015 in adult B-ALL (ROCKET Study): analyses of patient, protocol and product attributes., Proceedings of the 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017
- Alfred, 2016, Posterior reversible encephalopathy syndrome (PRES) after infusion of anti-Bcma CAR T Cells (CART-BCMA) for multiple myeloma: successful treatment with cyclophosphamide., Blood., 128, 10.1182/blood.V128.22.5702.5702 · doi:10.1182/blood.v128.22.5702.5702
Cited by
T cell receptor (TCR) signaling in health and disease
Shah, K., Al-Haidari, A., Sun, J., & Kazi, J. U. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00823-w · Cited by 604
γδ T cells: origin and fate, subsets, diseases and immunotherapy
Hu, Y., Hu, Q., Li, Y., Lu, L., Xiang, Z., Yin, Z., Kabelitz, D., & Wu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01653-8 · Cited by 382
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01702-9 · Cited by 349
GM-CSF: Master regulator of the T cell-phagocyte interface during inflammation
Ingelfinger, F., De Feo, D., & Becher, B. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101518 · Cited by 61
Remyelination in the central nervous system
Franklin, R. J. M., Bodini, B., & Goldman, S. A. (2024) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041371 · Cited by 40
Metadata
- Authors
- Siegler, E. L., & Kenderian, S. S.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-08-28
- Volume
- 11
- Pages
- 1973-1973
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3081687748
- Cited by
- 282
- References
- 90
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.